{
    "markdown": "<a id='51a81c5f-8ceb-4063-8038-81b8352dc87a'></a>\n\n21\n\n<a id='13ecd978-50b5-4589-9c73-1220d9e7b156'></a>\n\n(from copper gluconate) is also administered to each pa-\ntient.\n\n5 The density of the subject's lumbar vertebrae is\ndetermined by dual-energy x-ray absorptiometry. The human\nsubject is then administered 4 of the calcium tablets and\none trace mineral capsules comprised as above, each day for\n12 months. The mass of the subject's vertebrae is then\nremeasured, indicating a net increase in bone mass. The\n10 following results are achieved after 1 year.\n\nChange in Spine Bone Mineral Density\n\n<a id='50a63f3d-97a5-4557-bb99-bb8853bc9088'></a>\n\n<table><thead><tr><th></th><th>Treatments</th><th>Number<br>Of Patients</th><th>% Change<br>After 1 Year</th><th>Net<br>Increase<br>In<br>Bone Mass</th></tr></thead><tbody><tr><td>15</td><td>Calcium placebo/<br>Trace minerals placebo</td><td>42</td><td>-2.41 \u00b1 0.63</td><td>0.00</td></tr><tr><td></td><td>Calcium placebo/<br>trace minerals</td><td>38</td><td>-1.55 \u00b1 0.66</td><td>0.86</td></tr><tr><td>20</td><td>Calcium/trace minerals<br>placebo</td><td>34</td><td>-1.28 \u00b1 0.70</td><td>1.13</td></tr><tr><td></td><td>Calcium and trace minerals</td><td>37</td><td>-0.17 \u00b1 0.67</td><td>2.24</td></tr></tbody></table>\n\n<a id='f00590a1-b287-46f3-98aa-4ed94093a8da'></a>\n\n25 The table shows that the calcium and trace minerals\nsupplement affects bone density and shows a net bone build-\ning effect of about 2.24% compared to the placebo group.\nThe calcium trace mineral supplement effect is significant-\nly different from the dual placebo treatment at a 95%\nconfidence level. The dual placebo patients had at least a\n30 2% loss over the one year period, the calcium/trace miner-\nals patients showed little or no bone loss and thus a net\nincrease of bone mass.\n\n<a id='ac3d3b17-8bb6-4712-ab5f-c09783983afc'></a>\n\n35\n\n## Example II\n\n### Preparation of Calcium-Citrate-Malate\n\nA calcium-citrate-malate solution is prepared by dissolving 2 parts sucrose and then 0.1 part citric and 0.28 part malic acids in 28.19 parts water. Calcium\n\n<a id='96e420a9-e5e8-4047-8b9e-5894681ed6e5'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/pxyK0226",
    "chunks": [
        {
            "markdown": "<a id='51a81c5f-8ceb-4063-8038-81b8352dc87a'></a>\n\n21",
            "type": "marginalia",
            "id": "51a81c5f-8ceb-4063-8038-81b8352dc87a",
            "grounding": {
                "box": {
                    "left": 0.5415928363800049,
                    "top": 0.1222318634390831,
                    "right": 0.5744473934173584,
                    "bottom": 0.14190036058425903
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='13ecd978-50b5-4589-9c73-1220d9e7b156'></a>\n\n(from copper gluconate) is also administered to each pa-\ntient.\n\n5 The density of the subject's lumbar vertebrae is\ndetermined by dual-energy x-ray absorptiometry. The human\nsubject is then administered 4 of the calcium tablets and\none trace mineral capsules comprised as above, each day for\n12 months. The mass of the subject's vertebrae is then\nremeasured, indicating a net increase in bone mass. The\n10 following results are achieved after 1 year.\n\nChange in Spine Bone Mineral Density",
            "type": "text",
            "id": "13ecd978-50b5-4589-9c73-1220d9e7b156",
            "grounding": {
                "box": {
                    "left": 0.1331612467765808,
                    "top": 0.14653810858726501,
                    "right": 0.8302891850471497,
                    "bottom": 0.3626990020275116
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='50a63f3d-97a5-4557-bb99-bb8853bc9088'></a>\n\n<table><thead><tr><th></th><th>Treatments</th><th>Number<br>Of Patients</th><th>% Change<br>After 1 Year</th><th>Net<br>Increase<br>In<br>Bone Mass</th></tr></thead><tbody><tr><td>15</td><td>Calcium placebo/<br>Trace minerals placebo</td><td>42</td><td>-2.41 \u00b1 0.63</td><td>0.00</td></tr><tr><td></td><td>Calcium placebo/<br>trace minerals</td><td>38</td><td>-1.55 \u00b1 0.66</td><td>0.86</td></tr><tr><td>20</td><td>Calcium/trace minerals<br>placebo</td><td>34</td><td>-1.28 \u00b1 0.70</td><td>1.13</td></tr><tr><td></td><td>Calcium and trace minerals</td><td>37</td><td>-0.17 \u00b1 0.67</td><td>2.24</td></tr></tbody></table>",
            "type": "table",
            "id": "50a63f3d-97a5-4557-bb99-bb8853bc9088",
            "grounding": {
                "box": {
                    "left": 0.13348037004470825,
                    "top": 0.36763715744018555,
                    "right": 0.8275584578514099,
                    "bottom": 0.6035763621330261
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='f00590a1-b287-46f3-98aa-4ed94093a8da'></a>\n\n25 The table shows that the calcium and trace minerals\nsupplement affects bone density and shows a net bone build-\ning effect of about 2.24% compared to the placebo group.\nThe calcium trace mineral supplement effect is significant-\nly different from the dual placebo treatment at a 95%\nconfidence level. The dual placebo patients had at least a\n30 2% loss over the one year period, the calcium/trace miner-\nals patients showed little or no bone loss and thus a net\nincrease of bone mass.",
            "type": "text",
            "id": "f00590a1-b287-46f3-98aa-4ed94093a8da",
            "grounding": {
                "box": {
                    "left": 0.13228148221969604,
                    "top": 0.6154552102088928,
                    "right": 0.8305098414421082,
                    "bottom": 0.8107654452323914
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='ac3d3b17-8bb6-4712-ab5f-c09783983afc'></a>\n\n35\n\n## Example II\n\n### Preparation of Calcium-Citrate-Malate\n\nA calcium-citrate-malate solution is prepared by dissolving 2 parts sucrose and then 0.1 part citric and 0.28 part malic acids in 28.19 parts water. Calcium",
            "type": "text",
            "id": "ac3d3b17-8bb6-4712-ab5f-c09783983afc",
            "grounding": {
                "box": {
                    "left": 0.13185375928878784,
                    "top": 0.8131771683692932,
                    "right": 0.8314390182495117,
                    "bottom": 0.9225992560386658
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='96e420a9-e5e8-4047-8b9e-5894681ed6e5'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/pxyK0226",
            "type": "marginalia",
            "id": "96e420a9-e5e8-4047-8b9e-5894681ed6e5",
            "grounding": {
                "box": {
                    "left": 0.19965186715126038,
                    "top": 0.9751678705215454,
                    "right": 0.80143141746521,
                    "bottom": 0.9999836683273315
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='51a81c5f-8ceb-4063-8038-81b8352dc87a'></a>\n\n21\n\n<a id='13ecd978-50b5-4589-9c73-1220d9e7b156'></a>\n\n(from copper gluconate) is also administered to each pa-\ntient.\n\n5 The density of the subject's lumbar vertebrae is\ndetermined by dual-energy x-ray absorptiometry. The human\nsubject is then administered 4 of the calcium tablets and\none trace mineral capsules comprised as above, each day for\n12 months. The mass of the subject's vertebrae is then\nremeasured, indicating a net increase in bone mass. The\n10 following results are achieved after 1 year.\n\nChange in Spine Bone Mineral Density\n\n<a id='50a63f3d-97a5-4557-bb99-bb8853bc9088'></a>\n\n<table><thead><tr><th></th><th>Treatments</th><th>Number<br>Of Patients</th><th>% Change<br>After 1 Year</th><th>Net<br>Increase<br>In<br>Bone Mass</th></tr></thead><tbody><tr><td>15</td><td>Calcium placebo/<br>Trace minerals placebo</td><td>42</td><td>-2.41 \u00b1 0.63</td><td>0.00</td></tr><tr><td></td><td>Calcium placebo/<br>trace minerals</td><td>38</td><td>-1.55 \u00b1 0.66</td><td>0.86</td></tr><tr><td>20</td><td>Calcium/trace minerals<br>placebo</td><td>34</td><td>-1.28 \u00b1 0.70</td><td>1.13</td></tr><tr><td></td><td>Calcium and trace minerals</td><td>37</td><td>-0.17 \u00b1 0.67</td><td>2.24</td></tr></tbody></table>\n\n<a id='f00590a1-b287-46f3-98aa-4ed94093a8da'></a>\n\n25 The table shows that the calcium and trace minerals\nsupplement affects bone density and shows a net bone build-\ning effect of about 2.24% compared to the placebo group.\nThe calcium trace mineral supplement effect is significant-\nly different from the dual placebo treatment at a 95%\nconfidence level. The dual placebo patients had at least a\n30 2% loss over the one year period, the calcium/trace miner-\nals patients showed little or no bone loss and thus a net\nincrease of bone mass.\n\n<a id='ac3d3b17-8bb6-4712-ab5f-c09783983afc'></a>\n\n35\n\n## Example II\n\n### Preparation of Calcium-Citrate-Malate\n\nA calcium-citrate-malate solution is prepared by dissolving 2 parts sucrose and then 0.1 part citric and 0.28 part malic acids in 28.19 parts water. Calcium\n\n<a id='96e420a9-e5e8-4047-8b9e-5894681ed6e5'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/pxyK0226",
            "chunks": [
                "51a81c5f-8ceb-4063-8038-81b8352dc87a",
                "13ecd978-50b5-4589-9c73-1220d9e7b156",
                "50a63f3d-97a5-4557-bb99-bb8853bc9088",
                "f00590a1-b287-46f3-98aa-4ed94093a8da",
                "ac3d3b17-8bb6-4712-ab5f-c09783983afc",
                "96e420a9-e5e8-4047-8b9e-5894681ed6e5"
            ]
        }
    ],
    "grounding": {
        "51a81c5f-8ceb-4063-8038-81b8352dc87a": {
            "box": {
                "left": 0.5415928363800049,
                "top": 0.1222318634390831,
                "right": 0.5744473934173584,
                "bottom": 0.14190036058425903
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "13ecd978-50b5-4589-9c73-1220d9e7b156": {
            "box": {
                "left": 0.1331612467765808,
                "top": 0.14653810858726501,
                "right": 0.8302891850471497,
                "bottom": 0.3626990020275116
            },
            "page": 0,
            "type": "chunkText"
        },
        "50a63f3d-97a5-4557-bb99-bb8853bc9088": {
            "box": {
                "left": 0.13348037004470825,
                "top": 0.36763715744018555,
                "right": 0.8275584578514099,
                "bottom": 0.6035763621330261
            },
            "page": 0,
            "type": "chunkTable"
        },
        "f00590a1-b287-46f3-98aa-4ed94093a8da": {
            "box": {
                "left": 0.13228148221969604,
                "top": 0.6154552102088928,
                "right": 0.8305098414421082,
                "bottom": 0.8107654452323914
            },
            "page": 0,
            "type": "chunkText"
        },
        "ac3d3b17-8bb6-4712-ab5f-c09783983afc": {
            "box": {
                "left": 0.13185375928878784,
                "top": 0.8131771683692932,
                "right": 0.8314390182495117,
                "bottom": 0.9225992560386658
            },
            "page": 0,
            "type": "chunkText"
        },
        "96e420a9-e5e8-4047-8b9e-5894681ed6e5": {
            "box": {
                "left": 0.19965186715126038,
                "top": 0.9751678705215454,
                "right": 0.80143141746521,
                "bottom": 0.9999836683273315
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "pxyk0226_24.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 7068,
        "credit_usage": 3.0,
        "job_id": "eyajnpbu55pvtnqzdayo70guy",
        "version": "dpt-2-20250919"
    }
}